SCHEMBL4750067

SCHEMBL4750067

NC12CCCC1CN(c1c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c1F)C2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.55
ALDH1A1 P00352 4/20 0.53
POLB P06746 2/20 0.53
OPRM1 P35372 2/20 0.53
CHRM2 P08172 1/20 0.53
CHRM1 P11229 1/20 0.53
OPRD1 P41143 1/20 0.53
TOP2A P11388 6/20 0.51
TOP2B Q02880 6/20 0.51
KDM4E B2RXH2 3/20 0.49
HPGD P15428 3/20 0.49
HSD17B10 Q99714 2/20 0.49
PRKD3 O94806 1/20 0.49
ALOX15 P16050 1/20 0.49
CLK2 P49760 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2670480 1.00 KCNH2 (0.55) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL9779913 1.00 KCNH2 (0.55) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL8385634 0.95 KCNH2 (0.56) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL8383857 0.92 KCNH2 (0.57) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL7511355 0.88 KCNH2 (0.65) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL28391101 0.88 KCNH2 (0.63) KCNH2ALDH1A1POLBOPRM1KDM4E
SCHEMBL30415810 0.88 KCNH2 (0.63) KCNH2ALDH1A1POLBOPRM1KDM4E
SCHEMBL6168061 0.87 KCNH2 (0.63) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL9779883 0.87 KCNH2 (0.59) KCNH2ALDH1A1POLBOPRM1CHRM2
SCHEMBL7506628 0.86 ALDH1A1 (0.53) KCNH2ALDH1A1POLBOPRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-22 US disclosed
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-22 US disclosed
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US disclosed
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US disclosed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 KCNH2 193/4885ALDH1A1 2730/4885POLB 173/4885
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative NQO2, QDPR, IL4I1 KCNH2 193/4885ALDH1A1 2730/4885POLB 173/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 KCNH2 193/4885ALDH1A1 2730/4885POLB 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.